Welldoc kicked off March with the launch of four new patents and a major leap forward in AI-powered care. The company introduced “CGM-GPT,” a generative AI model designed to predict future glucose levels using real-time data from continuous glucose monitors (CGMs). Built specifically for mathematical tasks—unlike traditional large language models—CGM-GPT reflects Welldoc’s push to turn dense sensor data into actionable, personalized insights for individuals managing cardiometabolic conditions.
The release builds on Welldoc’s expanding research engine. In late 2024, the company shared findings from a new wave of clinical studies, including a model that predicted 3% weight loss with 93% accuracy and another that outperformed current glucose prediction methods by 50%. With over 90 peer-reviewed publications and 37 focused specifically on AI, Welldoc is advancing a strategy grounded in responsible innovation—fusing machine learning with real-world patient data to drive better outcomes.
As continuous monitoring technology becomes more widespread and patients expect care that adapts in real time, Welldoc is emerging as a key player in digital health’s next chapter. The company’s growing patent portfolio and AI-first development model are setting a new pace for how chronic conditions like diabetes and hypertension can be managed—with fewer assumptions, and far more personalization.
